ASM case reports · 2025
Microbiological treatment failure associated with macrolide-resistant Bordetella pertussis.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prabhakar David, Fong Winkie, Sim Eby M, Howard-Jones Annaleise R, Nguyen Trang, Dempsey Suzanne, Rockett Rebecca J, Kok Jen, Chen Sharon C-A, Outhred Alexander C, Sintchenko Vitali
Аннотация
BACKGROUND: Despite successful vaccination programs, many countries are experiencing a marked rise in pertussis cases since 2024, compounded by the emergence of macrolide-resistant Bordetella pertussis (MRBP). Here, we report the clinical, laboratory, and genomic features of MRBP isolated from a child with severe pertussis.
CASE SUMMARY: An 11-week-old term infant with pertussis who required intensive care unit support remained B. pertussis culture-positive despite azithromycin therapy. Pre- and post-treatment isolates demonstrated phenotypic drug resistance and carried known 23S rRNA macrolide-resistance conferring mutations.
CONCLUSION: The international spread of macrolide-resistant B. pertussis warrants the introduction of susceptibility testing for this pathogen.
CASE SUMMARY: An 11-week-old term infant with pertussis who required intensive care unit support remained B. pertussis culture-positive despite azithromycin therapy. Pre- and post-treatment isolates demonstrated phenotypic drug resistance and carried known 23S rRNA macrolide-resistance conferring mutations.
CONCLUSION: The international spread of macrolide-resistant B. pertussis warrants the introduction of susceptibility testing for this pathogen.